Akers Biosciences Inc (AKR)

 
This US company’s shares are traded by us as on the LSE. Income from them will not be treated as eligible for a reduced rate of tax. Learn more

AKR Share PerformanceMore

52 week high255.00 01/12/16
52 week low86.00 24/02/17
52 week change 5.00 (4.00%)
4 week volume139,134 29/03/17

Media for (AKR)

Presenter: Ray, Akers, Co-Founder & Executive Chairman
29/07/2014
Presenter: Ray, Akers, Co-Founder & Executive Chairman
16/05/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Issue of Equity

RNS Number: 1752D Akers Biosciences, Inc. 24 April 2017 April 24, 2017 This announcement contains inside information Akers Biosciences, Inc. Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, has received further conversion notices from warrant holders ...

Holding(s) in Company

RNS Number: 1895C Akers Biosciences, Inc. 11 April 2017 April 11, 2017 Akers Biosciences, Inc. Holdings in Company Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, was notified on April 7, 2017 that Empery Asset Management, LP has a shareholding of 724,000 common sh...

Akers Bio revenues up 40%

Akers Biosciences' total revenues rose by 40% to $2,960,912 in the year to the end of December. Akers Bio said growth was d...

Final Results

RNS Number: 1288C Akers Biosciences, Inc. 11 April 2017 April 11, 2017 This announcement contains inside information Akers Biosciences, Inc. Financial Results for the Year Ended December 31, 2016 Sales of Flagship Rapid HIT Test +85% over prior year Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers", "Akers Bio" or the "Company"), a developer of...

Notice of Results

RNS Number: 0756C Akers Biosciences, Inc. 10 April 2017 April 10, 2017 Akers Biosciences, Inc. Notice of FY 2016 Earnings Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, announces that the Company will publish its financial results for the year ended December 31, 2016 o...

Issue of Equity

RNS Number: 0604C Akers Biosciences, Inc. 10 April 2017 April 10, 2017 Akers Biosciences, Inc. Issue of Equity Further to the announcement of April 6, 2017 concerning the conversion of a further 3,300 warrants in the Company, Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technol...

Akers Bio marketing HIT rapid test in Puerto Rico

Akers Biosciences has begun marketing its rapid test for heparin-induced thrombocytopenia to hospital facilities in Puerto ...

Heparin PF4 Rapid Test in Puerto Rico

RNS Number: 9705B Akers Biosciences, Inc. 10 April 2017 10 April 2017 Akers Biosciences to Commercialize Heparin PF4 Rapid Test in Puerto Rico Large New U.S-aligned Market Opportunity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, announces that the Company h...

Equity Research (AKR)

Akers Biosciences Inc.
18/08/2016
Physiomics* (PYC.L) 0.04p £1.22m The computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials...
Akers Biosciences Inc.
11/08/2016
ValiRx (Val.L) 39p £4.37m The life science company, which focuses on clinical stage cancer therapeutic development has received regulatory approval for its VAL401 Phase IIB Clinical Trial in Georgia...

Latest discussion posts More

  • Re: RNS : new PIFA agreement

    Maybe turned the corner here
    30-Mar-2017
    Silveroil
  • RNS : new PIFA agreement

    Looks like a potentially lucrative agreement with a group of up to 300 New York hospitals to introduce the PIFA ...
    19-Dec-2016
    gretel
  • Exciting RNS just out

    Worth noting in particular that First Check are a subsidiary of the mighty Alere ...
    1-Dec-2016
    gretel

Users' HoldingsMore

Users who hold Akers Biosciences Inc also hold..
LLOYDS GRP.32%
ID:ISIN:GB00B142G99419%
BP16%
NATIONAL GRID16%
ORMONDE MINING12%

Codes & Symbols

ISINUS00973E1029
SymbolsAKR, LSE:AKR, AKR.L, AKR:LN, LON:AKR, XLON:AKR